• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR

Mauna Kea Technologies Appoints John Soto As Chief Operating Officer

by Zina | Feb 2, 2017 | News

Addition of Seasoned Medical Device Executive with Decades of Experience in U.S. and Global Markets Strengthens Global Leadership Team Paris, February 2, 2017 – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the...

Mauna Kea Technologies reports fourth quarter and full year 2016 sales

by Zina | Jan 24, 2017 | News

Click to read more

Half-yearly report on the liquidity contract with Gilbert Dupont

by Zina | Jan 2, 2017 | News

Paris, France, January 2, 2017 Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2016 the following assets appeared on the liquidity account: – Number of shares: 23,681 Cash balance of the liquidity account: €94,289.08 As a...
PERSEE Study demonstrates applicability of Cellvizio in surgical interventions for digestive cancers, triggering milestone payment from BpiFrance

PERSEE Study demonstrates applicability of Cellvizio in surgical interventions for digestive cancers, triggering milestone payment from BpiFrance

by Zina | Nov 30, 2016 | News

Results from PERSEE Study Published in Surgical Endoscopy and European Journal of Gastroenterology & Hepatology Mauna Kea Technologies receives milestone payment of €626,000 from BpiFrance Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, OTCQX: MKEAY)...

Mauna Kea Technologies secures an Equity Financing Facility

by Zina | Nov 17, 2016 | News

Click to read more
« Older Entries
Next Entries »

Articles récents

  • ‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center
  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}